Ipatasertib: Phase II data

A double-blind, placebo-controlled, international Phase II trial in 253 patients with metastatic CRPC previously treated with docetaxel showed that once-daily 400 mg

Read the full 225 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE